Veenat Imatinib 400 mg Tablets

About Veenat Imatinib 400 mg Tablets

Imatinib, the active component of Veenat pills, has a 400mg dosage. A tyrosine kinase inhibitor called imatinib is used to treat specific cancers. It is typically recommended for gastrointestinal stromal tumours (GISTs) and chronic myeloid leukaemia (CML).

Imatinib functions by inhibiting particular proteins that, particularly in tumours with particular genetic abnormalities, encourage the growth and division of cancer cells.

CML, or chronic myeloid leukaemia:

• In the chronic phase, Veenat is used to treat newly identified Philadelphia chromosome-positive (Ph+) CML.
• Additionally, it is given for CML patients who are in the accelerated phase, going through a blast crisis, or are intolerant to conventional treatments.

GISTs, or gastrointestinal stromal tumours

• Patients with metastatic or irresectable GISTs who are not responding to previous therapies are treated with veenat.

To manage any adverse effects and guarantee the best possible treatment results, regular medical monitoring is required. Under the supervision of a licenced healthcare practitioner, Veenat should be utilised.

Veenat may result in side effects, just like other medicine. Skin rashes, muscle cramps, nausea, vomiting, and diarrhoea are examples of frequent adverse effects. During the course of their Veenat treatment, patients should instantly notify their healthcare practitioner of any worrying symptoms or side effects. To manage potential adverse effects and maximise therapy effectiveness, routine blood tests and medical monitoring are required. 

FAQ